Literature DB >> 28110294

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic.

Marc S Sabatine1.   

Abstract

Entities:  

Year:  2017        PMID： 28110294     DOI： 10.1093/eurheartj/ehw572

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  4 in total

1.  Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.

Authors:  Usha G Mallya; Susan H Boklage; Andrew Koren; Thomas E Delea; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

2.  Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.

Authors:  Kathleen M Fox; Ming-Hui Tai; Karel Kostev; Maximilian Hatz; Yi Qian; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2017-12-22       Impact factor: 5.460

3.  'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.

Authors:  Lieven Annemans; Chris J Packard; Andrew Briggs; Kausik K Ray
Journal:  Eur Heart J       Date:  2018-07-14       Impact factor: 29.983

4.  Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.

Authors:  Jakob Solgaard Jensen; Peter Ejvin Weeke; Lia Evi Bang; Dan Eik Høfsten; Maria Sejersten Ripa; Anne-Marie Schjerning; Juliane Elizabeth Theilade; Lars Valeur Køber; Gunnar Hilmar Gislason; Jannik Pallisgaard
Journal:  BMJ Open       Date:  2019-04-01       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.